Abstract
There has been rapid development of clinical trials conducted on antivirals, immunomodulators, and other therapies against COVID-19. The rising number of trials has led to duplication and a need for curation of available outcomes from treatments that have been followed across the world. We have conducted a systematic review and meta analysis that focus on evaluating the clinical outcomes of repurposed drugs against COVID-19 including Tocilizumab, Remdesivir, Dexamethasome, Lopinavir-ritonavir, Favipiravir, Hydroxychloroquine and Convalescent plasma therapy. Twenty-nine articles were included in this study after thorough literature search and performed subgroup analyses based on disease severity levels. Random effects model was adopted to estimate overall treatment effect and heterogeneity. Subgroup analysis on mortality rate showed significant overall effect in the treatment group of studies having critically ill patients (p<0.01). Meta-regression analysis was performed to study the association of drug efficacy in patients with different comorbidities and factors that influence the patient’s prevalence in non-invasive and invasive ventilation support. Overall, our study confirmed that tocilizumab may probably reduce the mortality (<10%) of patients with COVID-19 with faster recovery time and reduce the risk of patients with lung disease in falling into oxygen support (P=0.02). Patients on Remdesivir showed no significant associations of comorbidities with risk of falling into oxygen supports. Hydroxychloroquine was found to be inefficacious in COVID-19 patients (OR 0.64; 95%CI [0.47-0.86]). Dexamethasone had marginal effect on overall mortality rate (OR 1.19; 95%CI [1.05-1.35]). There was also evidence suggesting that combination therapies (Serpin + Favipiravir) were helpful in reducing the mortality rate in COVID-19 patients under invasive support.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis do not require approval from ethical guidelines as the work did not involve patients directly
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be accessed on request
